CI-MPSC@EC2611A

KHOON GROUP

HARBOUR DIGITAL

PETRO-KING

GF HEALTHCARE

CONGYU INTE AGR

160 HEALTH

51WORLD

HUILI RES

KWONG MAN KEE

DOUMOB

688351

159898

02160

688016

00853

159883

02252

02172

562600

Shares of MicroPort Endovascular MedTech Group surged 10.2% to CNY111.80 after the US FDA granted Breakthrough Device Designation to its innovative stent graft system, expediting market approval. The Hector Multi-Branch Thoracic Aortic Stent Graft System aims for minimally invasive treatment of thoracic aortic lesions. MicroPort reported a 12% rise in net profit to CNY563 million last year, driven by innovative product launches and a 55% increase in overseas sales. The device has received EU certification and is in clinical trials in China, addressing high-risk aortic arch lesions with less invasive methods.

Yicai

MICROPORT EP

China Merchants CSI All Share Medical Apparatus and Instruments ETF

MP CARDIOFLOW-B

Endovastec

MICROPORT

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

MircroPort Medbot-B

MICROPORT NEURO

ChinaAMC CSI All Share Health Care Devices ETF

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

MICROPORT announced that its 40.32% subsidiary Endovastec achieved revenue of RMB 1.351 billion for the fiscal year 2025, an increase of 12% year-on-year. The net profit attributable to shareholders was RMB 563 million, a growth of 12.2%

AASTOCKS

MicroPort earned 563 million RMB last year, an increase of 12.2%

MicroPort CardioFlow Medtech Corp. has received shareholder approval for a share consolidation, reducing issued shares from approximately 6.37 billion to about 1.27 billion. This consolidation will take effect on 24 February 2026, aiming to enhance trading efficiency and price perception. Existing blue share certificates will remain valid but not for trading after new light-gold certificates are issued. The company will also adjust share options accordingly. The latest analyst rating for the stock (HK:2160) is a Sell with a price target of HK$0.74.

Tip Ranks

MicroPort CardioFlow Wins Shareholder Approval for Share Consolidation Effective 24 February

MicroPort CardioFlow has merged with MicroPort CRM to create a comprehensive platform focused on structural heart, cardiac rhythm management, and heart failure. This merger aims to enhance access to advanced cardiovascular technologies globally. The original content was published by MicroPort Scientific Corporation on February 10, 2026.

Reuters

MicroPort CardioFlow Merges with MicroPort CRM

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

MicroPort Scientific (HK:0853) has announced a positive profit alert, expecting a net profit of at least US$20 million for the year ending December 31, 2025, a turnaround from a net loss of approximately US$268 million the previous year. This improvement is driven by 70% revenue growth in its overseas business, enhanced gross margins from cost optimization, reduced operating expenses, and gains from subsidiary disposals. The stock currently holds a Hold rating with a price target of HK$11.00, reflecting a significant operational and financial recovery ahead of full results due by March 2026.

MicroPort Scientific Flags Return to Profit on Overseas Growth and Cost Cuts

MicroPort Scientific Corporation (HKG:853) has delivered a remarkable 119% return to shareholders over the past year, despite a recent 17% drop in share price in the last quarter. The stock surged 8.6% in the past week, adding HK$1.8 billion to its market cap. However, the company reported a 0.7% decline in revenue, raising questions about its long-term growth potential. Insider buying in the past year is a positive sign, but future earnings will be crucial for sustaining shareholder returns. Overall, the short-term gains contrast with a long-term TSR loss of 12% per year over five years.

Simplywall

MicroPort Scientific (HKG:853) delivers shareholders splendid 119% return over 1 year, surging 8.6% in the last week alone

01066

The overseas expansion of innovative drugs and BD transactions have driven the explosive growth of stock prices in the pharmaceutical sector. By 2025, net purchases from southbound funds are expected to reach HKD 1.4 trillion, with the Hong Kong Stock Exchange Healthcare Index increasing by 76% this year. Structural differentiation is evident in the biopharmaceutical sector, with companies possessing First-in-Class or Best-in-Class R&D pipelines being more favored. The medical devices and supplies sector has performed well, with representative companies such as WEIGAO GROUP and MICROPORT seeing increases of 38% and 76% respectively this year

BambooWorks

WEIGAO GROUP

BD transactions and policy dividends resonate, the pharmaceutical sector will have a strong rebound in 2025

A Chinese robot, developed by Shanghai MicroPort MedBot, successfully performed autonomous biliary surgery on a pig, marking a significant advancement in robotic surgery. The MedBot's Neuron AI model, trained on extensive surgical data, executed 88% of the procedure autonomously. While the surgery was supervised by human surgeons, the experiment does not imply safety or efficacy for human applications, as it lacks regulatory approval. Shares of MedBot fell nearly 2% following the announcement. This milestone highlights the growing role of AI in medical technology, alongside developments from other tech giants like Alibaba and Tencent.

SCMP

AI surgery: Chinese robot conducts complex operation on pig without human intervention

MICROPORT announced the termination of the merger with MICROPORT Neuroscience, stating that after appointing an independent non-executive director, the company believes it cannot control MICROPORT Neuroscience according to accounting policies but still maintains significant influence. The termination of the merger is expected to recognize gains from deemed disposal of the subsidiary

MicroPort terminates merger with MicroPort Neuroscience

MicroPort Scientific Corporation has deconsolidated MicroPort NeuroScientific Corporation after appointing an independent non-executive director to its board. This change means MicroPort Scientific no longer controls the target company but retains significant influence. The company will recognize any gain from the disposal of its subsidiary based on the fair value of its equity interest and the net asset value of the target company, pending final audit review.

MicroPort Scientific Deconsolidates NeuroScientific Corporation After Board Changes

MicroPort CardioFlow Reports Strong One-Year AltaValve TMVR Data as Device Advances in Global Trials